Philip Gribbon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1271253/publications.pdf

Version: 2024-02-01

64 papers	2,207 citations	257101 24 h-index	243296 44 g-index
69 all docs	69 docs citations	69 times ranked	3425 citing authors

#	Article	IF	Citations
1	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. Briefings in Bioinformatics, 2022, 23, .	3.2	7
2	The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Reports, 2022, 17, 307-320.	2.3	138
3	Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 1049.	1.8	13
4	Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain. Drugs, 2022, 82, 357-373.	4.9	11
5	Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities. ACS Pharmacology and Translational Science, 2022, 5, 226-239.	2.5	43
6	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. Scientific Data, 2022, 9, .	2.4	17
7	An automated and high-throughput-screening compatible pluripotent stem cell-based test platform for developmental and reproductive toxicity assessment of small molecule compounds. Cell Biology and Toxicology, 2021, 37, 229-243.	2.4	6
8	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Scientific Data, 2021, 8, 70.	2.4	65
9	A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. ACS Pharmacology and Translational Science, 2021, 4, 1079-1095.	2.5	44
10	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. ACS Pharmacology and Translational Science, 2021, 4, 1096-1110.	2.5	101
11	X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science, 2021, 372, 642-646.	6.0	240
12	Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. Life, 2021, 11, 810.	1.1	9
13	Droplet-based vitrification of adherent human induced pluripotent stem cells on alginate microcarrier influenced by adhesion time and matrix elasticity. Cryobiology, 2021, 103, 57-69.	0.3	4
14	Discovery pipelines for marine resources: an ocean of opportunity for biotechnology?. World Journal of Microbiology and Biotechnology, 2019, 35, 107.	1.7	10
15	Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology, 2019, 26, 1295-1305.e6.	2.5	10
16	Identification and Characterization of Approved Drugs and Drug-Like Compounds as Covalent Escherichia coli ClpP Inhibitors. International Journal of Molecular Sciences, 2019, 20, 2686.	1.8	5
17	High-Throughput Fluorescence Polarization Assay to Identify Ligands Using Purified G Protein-Coupled Receptor. SLAS Discovery, 2019, 24, 915-927.	1.4	12
18	Î±-Amino Diphenyl Phosphonates as Novel Inhibitors of Escherichia coli ClpP Protease. Journal of Medicinal Chemistry, 2019, 62, 774-797.	2.9	23

#	Article	IF	Citations
19	EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. SLAS Discovery, 2019, 24, 398-413.	1.4	12
20	The European Marine Biological Research Infrastructure Cluster: An Alliance of European Research Infrastructures to Promote the Blue Bioeconomy. Grand Challenges in Biology and Biotechnology, 2018, , 405-421.	2.4	5
21	In vitro and in silico analysis of the effects of <scp>D</scp>₂ receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations. British Journal of Pharmacology, 2018, 175, 4121-4136.	2.7	14
22	Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERBÎ±. Journal of Biological Methods, 2018, 5, e94.	1.0	10
23	A Label-Free Continuous Fluorescence-Based Assay for Monitoring Ornithine Decarboxylase Activity with a Synthetic Putrescine Receptor. SLAS Discovery, 2017, 22, 906-914.	1.4	23
24	Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience. Stem Cell Research, 2017, 20, 105-114.	0.3	51
25	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. European Journal of Medicinal Chemistry, 2017, 126, 1129-1135.	2.6	20
26	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery. ACS Omega, 2017, 2, 5666-5683.	1.6	24
27	A high-content small molecule screen identifies novel inducers of definitive endoderm. Molecular Metabolism, 2017, 6, 640-650.	3.0	32
28	The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor. Frontiers in Pharmacology, 2017, 8, 667.	1.6	31
29	Establishing the Secondary Metabolite Profile of the Marine Fungus: Tolypocladium geodes sp. MF458 and Subsequent Optimisation of Bioactive Secondary Metabolite Production. Marine Drugs, 2017, 15, 84.	2.2	27
30	Biophysical characterization of E. coli TolC interaction with the known blocker hexaamminecobalt. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2702-2709.	1.1	21
31	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. Journal of Medicinal Chemistry, 2016, 59, 7598-7616.	2.9	41
32	Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase. Journal of Biomolecular Screening, 2016, 21, 689-694.	2.6	13
33	Risk mitigation in academic drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 333-336.	2.5	5
34	Towards a hit for every target. Nature Reviews Drug Discovery, 2016, 15, 1-2.	21.5	27
35	Stem cell reprogramming: Basic implications and future perspective for movement disorders. Movement Disorders, 2015, 30, 301-312.	2.2	5
36	A Phenotypic Screening Approach to Identify Anticancer Compounds Derived from Marine Fungi. Assay and Drug Development Technologies, 2014, 12, 162-175.	0.6	9

#	Article	IF	Citations
37	Development of a Colorimetric and a Fluorescence Phosphatase-Inhibitor Assay Suitable for Drug Discovery Approaches. Journal of Biomolecular Screening, 2013, 18, 899-909.	2.6	18
38	Development of an Assay for Complex I/Complex III of the Respiratory Chain Using Solid Supported Membranes and Its Application in Mitochondrial Toxicity Screening in Drug Discovery. Assay and Drug Development Technologies, 2011, 9, 147-156.	0.6	2
39	A Bioluminogenic HDAC Activity Assay: Validation and Screening. Journal of Biomolecular Screening, 2011, 16, 1227-1235.	2.6	37
40	Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery. Expert Opinion on Drug Discovery, 2010, 5, 681-690.	2.5	21
41	Induced pluripotent stem cells: a new tool for toxicology screening?. Archives of Toxicology, 2009, 83, 641-644.	1.9	25
42	High-throughput hit finding and compound-profiling technologies for academic drug discovery. Drug Discovery Today: Technologies, 2008, 5, e3-e7.	4.0	4
43	Hyaluronan Binding to Link Module of TSG-6 and to G1 Domain of Aggrecan Is Differently Regulated by pH. Journal of Biological Chemistry, 2008, 283, 32294-32301.	1.6	28
44	Feasibility study using surface-enhanced Raman spectroscopy for the quantitative detection of tyrosine and serine phosphorylation. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 912-918.	1.1	30
45	Analysing the Output from Primary Screening. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 331-337.	0.6	4
46	The Application of Fluorescence Lifetime Readouts in High-Throughput Screening. Journal of Biomolecular Screening, 2006, 11, 765-772.	2.6	20
47	A Novel Method for Analyzing [Ca2+] Flux Kinetics in High-Throughput Screening. Journal of Biomolecular Screening, 2006, 11, 511-518.	2.6	7
48	High-throughput drug discovery: What can we expect from HTS?. Drug Discovery Today, 2005, 10, 17-22.	3.2	162
49	NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening. Journal of Biomolecular Screening, 2005, 10, 573-580.	2.6	21
50	Evaluating Real-Life High-Throughput Screening Data. Journal of Biomolecular Screening, 2005, 10, 99-107.	2.6	73
51	Experiences in Implementing uHTS - Cutting Edge Technology Meets the Real World. Current Drug Discovery Technologies, 2004, 1, 27-35.	0.6	12
52	Fluorescence readouts in HTS: no gain without pain?. Drug Discovery Today, 2003, 8, 1035-1043.	3.2	122
53	Measuring Intracellular Calcium Fluxes in High Throughput Mode. Combinatorial Chemistry and High Throughput Screening, 2003, 6, 355-362.	0.6	53
54	Development of a 1-Î¼l Scale Assay for Mitogen-Activated Kinase Kinase 7 Using 2-D Fluorescence Intensity Distribution Analysis Anisotropy. Journal of Biomolecular Screening, 2002, 7, 419-428.	2.6	14

#	Article	IF	Citations
55	THE APPLICATION OF CONFOCAL MICROSCOPY TO THE STUDY OF LIPOSOME ADSORPTION ONTO BACTERIAL BIOFILMS. Journal of Liposome Research, 2002, 12, 285-300.	1.5	44
56	Novel Confocal-FRAP Analysis of Carbohydrate-Protein Interactions Within the Extracellular Matrix. , 2001, 171, 487-494.		3
57	Confocal-FRAP Analysis of ECM Molecular Interactions. , 2000, 139, 83-93.		3
58	The analysis of intermolecular interactions in concentrated hyaluronan solutions suggest no evidence for chain-chain association. Biochemical Journal, 2000, 350 Pt 1, 329-35.	1.7	20
59	The Molecular Basis of the Solution Properties of Hyaluronan Investigated by Confocal Fluorescence Recovery After Photobleaching. Biophysical Journal, 1999, 77, 2210-2216.	0.2	104
60	New approaches to the investigation of hyaluronan networks. Biochemical Society Transactions, 1999, 27, 124-127.	1.6	8
61	Macromolecular Diffusion of Biological Polymers Measured by Confocal Fluorescence Recovery after Photobleaching. Biophysical Journal, 1998, 75, 1032-1039.	0.2	126
62	Alpha-1-acid (AAG, orosomucoid) glycoprotein: interaction with bacterial lipopolysaccharide and protection from sepsis. Inflammation, 1997, 21, 69-82.	1.7	61
63	Time dependent effects of trypsin treatment of human red cells. Clinical Hemorheology and Microcirculation, 1993, 13, 473-479.	0.9	1
64	Electronic laboratory notebooks in a publicâ€“private partnership. PeerJ Computer Science, 0, 2, e83.	2.7	2